Brazilian health regulator Anvisa has brought a halt to a trial of a coronavirus vaccine being developed by Sinovac.
The reason for this action is a serious adverse event in the study of the Chinese firm’s CoronaVac candidate, according to the Anvisa website.
It has also been reported that the death is not related to the vaccine, leading the head of Sao Paulo's medical research institute Butantan, which is running the COVID-19 vaccine trials in Brazil, to express surprise at the Anvisa decision.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze